Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant + vancomycin
- Development stage
- Unknown
- Lead developer
- ProgenaBiome
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
fecal microbiota transplant + vancomycin-ProgenaBiome refers to a sequential combination therapy protocol developed by ProgenaBiome for the treatment of Autism Spectrum Disorder (ASD). The regimen involves an initial course of the glycopeptide antibiotic vancomycin, which is used to reduce the abundance of potentially pathogenic or non-normative gut bacteria. This is followed by a fecal microbiota transplant (FMT) to introduce a diverse and healthy microbial community from a donor. The therapeutic rationale is based on the hypothesis that modulating the gut microbiome can influence the gut-brain axis, thereby alleviating both gastrointestinal and behavioral symptoms associated with ASD.
- Other names
- FMT + vancomycinvancomycin followed by fecal microbiota transplant
02
Targets
D-Ala-D-Ala (D-Ala-D-Ala terminus)
Beyond the preview
Go deeper on fecal microbiota transplant + vancomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant + vancomycin.